FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB A	PPF	ROV	Ά
-------	-----	-----	---

Ì	OMB Number:	3235-0287
	Estimated average burden	
	hours per response:	0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [ BRTX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Silva Francisco  (Last) (First) (Middle)  40 MARCUS DRIVE				X	Direct	ctor	X	10% Owner	
		(Middle)		X	Office below	cer (give title w)		Other (specify below)	
		(iviluale)	3. Date of Earliest Transaction (Month/Day/Year) 02/17/2023	VP of Research and Development					
(Street) MELVILLE	NY	11747	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	, , ,			Person	
(City)	(State)	(Zip)			Form	n filed by More than	One	Reporting Person	

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount (A) or (D) Price			(Instr. 3 and 4)		(Instr. 4)
Common Stock								166,046 <sup>(1)</sup>	D	
Common Stock								12,136	I	IRA

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction 3A. Deemed 4. 5. Number of 6. Date Exercisable and 7. Title and Amount of 8. Price of 9. Number of 10. 11. Nature													44 51 4		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)		Derivative Securitie Acquired Disposed	5. Number of Derivative Expiration Date (Month/Day/Year) Acquired (A) or Disposed of (D) Instr. 3, 4 and 5)		ate	7. Title and Am Securities Und Derivative Sec and 4)	lerlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$3,000							(2)	10/04/2023	Common Stock	1		1	D	
Stock Option	\$3,000							(2)	02/18/2024	Common Stock	3		3	D	
Stock Option	\$3,000							03/12/2014	03/11/2024	Common Stock	1		1	D	
Stock Option	\$3,000							(2)	10/23/2024	Common Stock	9		9	D	
Stock Option	\$3,000							(2)	09/04/2025	Common Stock	6		6	D	
Stock Option	\$3,000							(2)	06/10/2026	Common Stock	15		15	D	
Stock Option	\$3,000							(2)	07/12/2027	Common Stock	20		20	D	
Stock Option	\$3,000							(2)	10/29/2028	Common Stock	25		25	D	
Stock Option	\$5.08							(3)	03/18/2031	Common Stock	293,479		293,479	D	
Stock Option	\$5.08							(4)	11/04/2031	Common Stock	42,059		42,059	D	
Stock Option	\$2.91	02/17/2023		A		106,762		(5)	02/17/2033	Common Stock	106,762	\$0	106,762	D	

# Explanation of Responses:

- 1. Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024
- 2. The option is currently exercisable.
- 3. The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
- 4. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.
- 5. The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.

/s/ Francisco Silva

02/17/2023

\*\* Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.